Pacific Biosciences of California, Inc.

NasdaqGS:PACB 株式レポート

時価総額:US$603.9m

Pacific Biosciences of California 配当と自社株買い

配当金 基準チェック /06

Pacific Biosciences of California配当金を支払った記録がありません。

主要情報

n/a

配当利回り

-2.1%

バイバック利回り

総株主利回り-2.1%
将来の配当利回り0%
配当成長n/a
次回配当支払日n/a
配当落ち日n/a
一株当たり配当金n/a
配当性向n/a

最近の配当と自社株買いの更新

更新なし

Recent updates

Pacific Biosciences' Cost Cuts Won't Offset Rising Competition

Nov 12

Pacific Biosciences of California, Inc. (NASDAQ:PACB) Stock Rockets 56% But Many Are Still Ignoring The Company

Nov 07
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Stock Rockets 56% But Many Are Still Ignoring The Company

Health Check: How Prudently Does Pacific Biosciences of California (NASDAQ:PACB) Use Debt?

Oct 16
Health Check: How Prudently Does Pacific Biosciences of California (NASDAQ:PACB) Use Debt?

Even With A 37% Surge, Cautious Investors Are Not Rewarding Pacific Biosciences of California, Inc.'s (NASDAQ:PACB) Performance Completely

Sep 20
Even With A 37% Surge, Cautious Investors Are Not Rewarding Pacific Biosciences of California, Inc.'s (NASDAQ:PACB) Performance Completely

Pacific Biosciences: A Speculative Play On Long-Read Genomics Sequencing

Aug 21

Take Care Before Jumping Onto Pacific Biosciences of California, Inc. (NASDAQ:PACB) Even Though It's 33% Cheaper

Jul 02
Take Care Before Jumping Onto Pacific Biosciences of California, Inc. (NASDAQ:PACB) Even Though It's 33% Cheaper

We Think Pacific Biosciences of California (NASDAQ:PACB) Has A Fair Chunk Of Debt

Jun 08
We Think Pacific Biosciences of California (NASDAQ:PACB) Has A Fair Chunk Of Debt

Pacific Biosciences: Navigating Rough Waters In Gene Sequencing Seas

Jun 03

These Analysts Think Pacific Biosciences of California, Inc.'s (NASDAQ:PACB) Sales Are Under Threat

Apr 25
These Analysts Think Pacific Biosciences of California, Inc.'s (NASDAQ:PACB) Sales Are Under Threat

It's Down 25% But Pacific Biosciences of California, Inc. (NASDAQ:PACB) Could Be Riskier Than It Looks

Apr 16
It's Down 25% But Pacific Biosciences of California, Inc. (NASDAQ:PACB) Could Be Riskier Than It Looks

Pacific Biosciences' Pivot: From Shareholder Dilution To Expansion And Leadership

Mar 19

Pacific Biosciences: Strong Cash And Doubling Revenue Signal Investment Growth

Feb 08

With A 34% Price Drop For Pacific Biosciences of California, Inc. (NASDAQ:PACB) You'll Still Get What You Pay For

Feb 01
With A 34% Price Drop For Pacific Biosciences of California, Inc. (NASDAQ:PACB) You'll Still Get What You Pay For

What You Can Learn From Pacific Biosciences of California, Inc.'s (NASDAQ:PACB) P/S

Dec 18
What You Can Learn From Pacific Biosciences of California, Inc.'s (NASDAQ:PACB) P/S

Does Pacific Biosciences of California (NASDAQ:PACB) Have A Healthy Balance Sheet?

Nov 13
Does Pacific Biosciences of California (NASDAQ:PACB) Have A Healthy Balance Sheet?

The Price Is Right For Pacific Biosciences of California, Inc. (NASDAQ:PACB) Even After Diving 27%

Aug 28
The Price Is Right For Pacific Biosciences of California, Inc. (NASDAQ:PACB) Even After Diving 27%

Is Pacific Biosciences of California, Inc. (NASDAQ:PACB) Trading At A 32% Discount?

Jul 31
Is Pacific Biosciences of California, Inc. (NASDAQ:PACB) Trading At A 32% Discount?

Is It Time To Consider Buying Pacific Biosciences of California, Inc. (NASDAQ:PACB)?

Jul 06
Is It Time To Consider Buying Pacific Biosciences of California, Inc. (NASDAQ:PACB)?

Pacific Biosciences of California (NASDAQ:PACB) Is Carrying A Fair Bit Of Debt

May 25
Pacific Biosciences of California (NASDAQ:PACB) Is Carrying A Fair Bit Of Debt

Is Now The Time To Look At Buying Pacific Biosciences of California, Inc. (NASDAQ:PACB)?

Mar 29
Is Now The Time To Look At Buying Pacific Biosciences of California, Inc. (NASDAQ:PACB)?

Is Pacific Biosciences of California, Inc. (NASDAQ:PACB) Worth US$8.8 Based On Its Intrinsic Value?

Feb 26
Is Pacific Biosciences of California, Inc. (NASDAQ:PACB) Worth US$8.8 Based On Its Intrinsic Value?

決済の安定と成長

配当データの取得

安定した配当: PACBの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。

増加する配当: PACBの配当金が増加しているかどうかを判断するにはデータが不十分です。


配当利回り対市場

Pacific Biosciences of California 配当利回り対市場
PACB 配当利回りは市場と比べてどうか?
セグメント配当利回り
会社 (PACB)n/a
市場下位25% (US)1.4%
市場トップ25% (US)4.4%
業界平均 (Life Sciences)0.5%
アナリスト予想 (PACB) (最長3年)0%

注目すべき配当: PACBは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。

高配当: PACBは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。


株主への利益配当

収益カバレッジ: PACBの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。


株主配当金

キャッシュフローカバレッジ: PACBが配当金を報告していないため、配当金の持続可能性を計算できません。


高配当企業の発掘